| Referral to treatment | National Optimal Lung Cancer Pathway For suspected and confirmed lung cancer: Referral to treatment UPDATE 2017 Version 2.0 | Start pathway | View the flowchart | Read more |
|---|---|---|---|---|
| NSCLC Clinical Stage IA and IB | Start pathway | View the flowchart | Read more | |
| NSCLC Clinical Stage IIA, IIB | and Resectable IIIA Excluding Pancoast Tumors for Patients Who Have Not Received Neoadjuvant Treatment | Start pathway | View the flowchart | Read more |
| NSCLC Clinically Resectable Stage IIA, IIB, and IIIA | Excluding Pancoast Tumors | Start pathway | View the flowchart | Read more |
| NSCLC Clinically Resectable Stage IIA, IIB, and IIIA | Excluding Pancoast Tumors | Start pathway | View the flowchart | Read more |
| NSCLC Clinical Stage III | Unresectable Multiple Level N2, Bulky N2, Any N3, Any T4 Due To Tumor Invasion Into Adjacent Structure First Line | Start pathway | View the flowchart | Read more |
| NSCLC Stage IVA M1b | Single Extrathoracic Site or M1a Due To A Contralateral Nodule at Presentation | Start pathway | View the flowchart | Read more |
| Molecular Testing | Start pathway | View the flowchart | Read more | |
| NSCLC Stage IVA | Due to Pericardial/Pleural Effusion and IVB Mutation Positive | Start pathway | View the flowchart | Read more |
| NSCLC Stage IVA | Due to Pericardial/Pleural Effusion and IVB Mutation Negative | Start pathway | View the flowchart | Read more |